Slavishly following long-held guidelines for diagnosing the cause of arthritis-related back pain is resulting in excessive tests, delays in pain relief and wasteful spending of as much as $10,000 per patient, new Johns Hopkins-led research suggests.Arthritis is a common cause of back pain, though difficult to precisely diagnose, experts say, because of the poor correlation between a finding of ...

Slavishly following long-held guidelines for diagnosing the cause of arthritis-related back pain is resulting in excessive tests, delays in pain relief and wasteful spending of as much as $10,000 per patient, new Johns Hopkins-led research suggests.

Washington, July 24 : A new research suggests that slavishly following long-held guidelines for diagnosing the cause of arthritis-related back pain is resulting in excessive tests, delays in pain relief and wasteful spending of as much as 10,000 dollars per patient.

Many people with arthritis-related back pain might be prevented from getting long-lasting pain relief under the current management guidelines, US researchers said Friday.

LONDON (SHARECAST) - Anglo-Swedish drugs giant AstraZeneca said the US Food and Drug Administration (FDA) has approved VIMOVO, the pain relief pill for arthritis sufferers.